Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
37
GUD.TO Quote, Financials, Valuation and Earnings
Last price:
$6.00
Seasonality move
:
-3.59%
Day range:
$5.97 - $6.05
52-week range:
$5.11 - $6.55
Dividend yield:
0%
P/E ratio:
1,890.63x
P/S ratio:
1.45x
P/B ratio:
0.78x
Volume:
42.3K
Avg. volume:
48.3K
1-year change:
16.28%
Market cap:
$595.7M
Revenue:
$371.3M
EPS (TTM):
-$0.04
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GUD.TO
Knight Therapeutics, Inc.
|
$114.6M | -- | 22% | -90.68% | $7.93 |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -- | -- | -- | -- |
|
PRN.TO
Profound Medical Corp.
|
$9.8M | -$0.38 | 89.28% | -44.37% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GUD.TO
Knight Therapeutics, Inc.
|
$6.00 | $7.93 | $595.7M | 1,890.63x | $0.00 | 0% | 1.45x |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
$0.0250 | -- | $256.9K | 0.65x | $0.00 | 0% | -- |
|
PRN.TO
Profound Medical Corp.
|
$10.46 | -- | $315.8M | -- | $0.00 | 0% | 15.20x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GUD.TO
Knight Therapeutics, Inc.
|
12.17% | -0.657 | 18.13% | 1.40x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-3.43% | 1.456 | 20.53% | 0.00x |
|
PRN.TO
Profound Medical Corp.
|
12.89% | 0.573 | 3.22% | 3.30x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GUD.TO
Knight Therapeutics, Inc.
|
$40.4M | $646K | -0.41% | -0.45% | 0.53% | $7.7M |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -$72.1K | -- | -- | -- | -$92.1K |
|
PRN.TO
Profound Medical Corp.
|
$5.4M | -$12.3M | -81.8% | -91.61% | -168.52% | -$13.2M |
Knight Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns GUD.TO or COOL.CX?
Core One Labs, Inc. has a net margin of -3.12% compared to Knight Therapeutics, Inc.'s net margin of --. Knight Therapeutics, Inc.'s return on equity of -0.45% beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GUD.TOKnight Therapeutics, Inc.33.21% -$0.04 $873M COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About GUD.TO or COOL.CX?
Knight Therapeutics, Inc. has a consensus price target of $7.93, signalling upside risk potential of 31.19%. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Knight Therapeutics, Inc. has higher upside potential than Core One Labs, Inc., analysts believe Knight Therapeutics, Inc. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GUD.TOKnight Therapeutics, Inc.2 1 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is GUD.TO or COOL.CX More Risky?
Knight Therapeutics, Inc. has a beta of 0.116, which suggesting that the stock is 88.421% less volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock GUD.TO or COOL.CX?
Knight Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Knight Therapeutics, Inc. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GUD.TO or COOL.CX?
Knight Therapeutics, Inc. quarterly revenues are $121.5M, which are larger than Core One Labs, Inc. quarterly revenues of --. Knight Therapeutics, Inc.'s net income of -$3.8M is higher than Core One Labs, Inc.'s net income of --. Notably, Knight Therapeutics, Inc.'s price-to-earnings ratio is 1,890.63x while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Knight Therapeutics, Inc. is 1.45x versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GUD.TOKnight Therapeutics, Inc.1.45x 1,890.63x $121.5M -$3.8M COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns GUD.TO or CURE.X.CX?
Biocure Technology has a net margin of -3.12% compared to Knight Therapeutics, Inc.'s net margin of --. Knight Therapeutics, Inc.'s return on equity of -0.45% beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GUD.TOKnight Therapeutics, Inc.33.21% -$0.04 $873M CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About GUD.TO or CURE.X.CX?
Knight Therapeutics, Inc. has a consensus price target of $7.93, signalling upside risk potential of 31.19%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Knight Therapeutics, Inc. has higher upside potential than Biocure Technology, analysts believe Knight Therapeutics, Inc. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings GUD.TOKnight Therapeutics, Inc.2 1 0 CURE.X.CXBiocure Technology0 0 0 -
Is GUD.TO or CURE.X.CX More Risky?
Knight Therapeutics, Inc. has a beta of 0.116, which suggesting that the stock is 88.421% less volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GUD.TO or CURE.X.CX?
Knight Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Knight Therapeutics, Inc. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GUD.TO or CURE.X.CX?
Knight Therapeutics, Inc. quarterly revenues are $121.5M, which are larger than Biocure Technology quarterly revenues of --. Knight Therapeutics, Inc.'s net income of -$3.8M is higher than Biocure Technology's net income of --. Notably, Knight Therapeutics, Inc.'s price-to-earnings ratio is 1,890.63x while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Knight Therapeutics, Inc. is 1.45x versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GUD.TOKnight Therapeutics, Inc.1.45x 1,890.63x $121.5M -$3.8M CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns GUD.TO or HEAL.CX?
has a net margin of -3.12% compared to Knight Therapeutics, Inc.'s net margin of --. Knight Therapeutics, Inc.'s return on equity of -0.45% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GUD.TOKnight Therapeutics, Inc.33.21% -$0.04 $873M HEAL.CX-- -- -- -
What do Analysts Say About GUD.TO or HEAL.CX?
Knight Therapeutics, Inc. has a consensus price target of $7.93, signalling upside risk potential of 31.19%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Knight Therapeutics, Inc. has higher upside potential than , analysts believe Knight Therapeutics, Inc. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings GUD.TOKnight Therapeutics, Inc.2 1 0 HEAL.CX0 0 0 -
Is GUD.TO or HEAL.CX More Risky?
Knight Therapeutics, Inc. has a beta of 0.116, which suggesting that the stock is 88.421% less volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GUD.TO or HEAL.CX?
Knight Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Knight Therapeutics, Inc. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GUD.TO or HEAL.CX?
Knight Therapeutics, Inc. quarterly revenues are $121.5M, which are larger than quarterly revenues of --. Knight Therapeutics, Inc.'s net income of -$3.8M is higher than 's net income of --. Notably, Knight Therapeutics, Inc.'s price-to-earnings ratio is 1,890.63x while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Knight Therapeutics, Inc. is 1.45x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GUD.TOKnight Therapeutics, Inc.1.45x 1,890.63x $121.5M -$3.8M HEAL.CX-- -- -- --
-
Which has Higher Returns GUD.TO or NSHS.CX?
NanoSphere Health Sciences, Inc. has a net margin of -3.12% compared to Knight Therapeutics, Inc.'s net margin of --. Knight Therapeutics, Inc.'s return on equity of -0.45% beat NanoSphere Health Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GUD.TOKnight Therapeutics, Inc.33.21% -$0.04 $873M NSHS.CXNanoSphere Health Sciences, Inc.-- -$0.00 -$1.8M -
What do Analysts Say About GUD.TO or NSHS.CX?
Knight Therapeutics, Inc. has a consensus price target of $7.93, signalling upside risk potential of 31.19%. On the other hand NanoSphere Health Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Knight Therapeutics, Inc. has higher upside potential than NanoSphere Health Sciences, Inc., analysts believe Knight Therapeutics, Inc. is more attractive than NanoSphere Health Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GUD.TOKnight Therapeutics, Inc.2 1 0 NSHS.CXNanoSphere Health Sciences, Inc.0 0 0 -
Is GUD.TO or NSHS.CX More Risky?
Knight Therapeutics, Inc. has a beta of 0.116, which suggesting that the stock is 88.421% less volatile than S&P 500. In comparison NanoSphere Health Sciences, Inc. has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.292%.
-
Which is a Better Dividend Stock GUD.TO or NSHS.CX?
Knight Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoSphere Health Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Knight Therapeutics, Inc. pays -- of its earnings as a dividend. NanoSphere Health Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GUD.TO or NSHS.CX?
Knight Therapeutics, Inc. quarterly revenues are $121.5M, which are larger than NanoSphere Health Sciences, Inc. quarterly revenues of --. Knight Therapeutics, Inc.'s net income of -$3.8M is lower than NanoSphere Health Sciences, Inc.'s net income of -$13.1K. Notably, Knight Therapeutics, Inc.'s price-to-earnings ratio is 1,890.63x while NanoSphere Health Sciences, Inc.'s PE ratio is 0.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Knight Therapeutics, Inc. is 1.45x versus -- for NanoSphere Health Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GUD.TOKnight Therapeutics, Inc.1.45x 1,890.63x $121.5M -$3.8M NSHS.CXNanoSphere Health Sciences, Inc.-- 0.65x -- -$13.1K
-
Which has Higher Returns GUD.TO or PRN.TO?
Profound Medical Corp. has a net margin of -3.12% compared to Knight Therapeutics, Inc.'s net margin of -150.82%. Knight Therapeutics, Inc.'s return on equity of -0.45% beat Profound Medical Corp.'s return on equity of -91.61%.
Company Gross Margin Earnings Per Share Invested Capital GUD.TOKnight Therapeutics, Inc.33.21% -$0.04 $873M PRN.TOProfound Medical Corp.74.32% -$0.37 $51.3M -
What do Analysts Say About GUD.TO or PRN.TO?
Knight Therapeutics, Inc. has a consensus price target of $7.93, signalling upside risk potential of 31.19%. On the other hand Profound Medical Corp. has an analysts' consensus of -- which suggests that it could grow by 105.55%. Given that Profound Medical Corp. has higher upside potential than Knight Therapeutics, Inc., analysts believe Profound Medical Corp. is more attractive than Knight Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GUD.TOKnight Therapeutics, Inc.2 1 0 PRN.TOProfound Medical Corp.4 0 0 -
Is GUD.TO or PRN.TO More Risky?
Knight Therapeutics, Inc. has a beta of 0.116, which suggesting that the stock is 88.421% less volatile than S&P 500. In comparison Profound Medical Corp. has a beta of 0.068, suggesting its less volatile than the S&P 500 by 93.156%.
-
Which is a Better Dividend Stock GUD.TO or PRN.TO?
Knight Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Profound Medical Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Knight Therapeutics, Inc. pays -- of its earnings as a dividend. Profound Medical Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GUD.TO or PRN.TO?
Knight Therapeutics, Inc. quarterly revenues are $121.5M, which are larger than Profound Medical Corp. quarterly revenues of $7.3M. Knight Therapeutics, Inc.'s net income of -$3.8M is higher than Profound Medical Corp.'s net income of -$11M. Notably, Knight Therapeutics, Inc.'s price-to-earnings ratio is 1,890.63x while Profound Medical Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Knight Therapeutics, Inc. is 1.45x versus 15.20x for Profound Medical Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GUD.TOKnight Therapeutics, Inc.1.45x 1,890.63x $121.5M -$3.8M PRN.TOProfound Medical Corp.15.20x -- $7.3M -$11M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
